Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases

Hao Liu1, Li-Hong Chen2, Zhi-Hui Zhang3, Ning Wang1, Si-Hui Zhuang2, Hao Chen1, Jin Du2, Li-Juan Pang2* and Yan Qi1,2*

1Department of Pathology, Shihezi University School of Medicine & the First Affiliated Hospital to Shihezi University School of Medicine, Shihezi, Xinjiang, China, 2Department of Pathology, Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, China, 3Department of Thoracic Surgery, Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang, Guangdong, China

Molecular targeting and immunotherapy provide durable responses for advanced lung cancer clinical therapy in many patients. However, the mechanisms of occurrence of progressive disease and resistance to targeted therapy and immunotherapy have not been elucidated. Herein, we report two cases of small cell transformation of non-small cell lung cancer (NSCLC) after targeted therapy or immunotherapy. The first case was a 63-year-old female patient presenting with cough and expectoration. Left lung invasive adenocarcinoma was diagnosed after left lung tumor biopsy. After epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted therapy for almost 2 years, disease progression and symptom aggravation were observed. Pathological and immunohistochemical staining results after biopsy revealed small cell lung cancer (SCLC). The second case was a 75-year-old male patient diagnosed with stage IV squamous cell carcinoma of the lung, who received carboplatin/paclitaxel adjuvant chemotherapy and pembrolizumab treatment with partial response. Disease progression and metastasis occurred within 15 cycles of immunotherapy. Computed tomography revealed a lower left lung tumor. Cytological examination of lung lavage fluid and biopsy under thoracoscope revealed SCLC. In conclusion, histological transformation to SCLC is a potential mechanism of NSCLC resistance to targeted therapy or immunotherapy. During treatment, clinicians should monitor serum tumor markers or genome sequencing, particularly in patients with disease...
progression, as this may be beneficial for early detection of SCLC transformation. Repeated biopsy can be performed if necessary, and the therapeutic regimen can be adjusted in a timely manner according to the results of molecular pathological tests for personalization and whole-process management.

KEYWORDS
lung cancer, EGFR-TKI, PD-1 inhibitors, histomorphological transformation, targeted therapy, immunotherapy

Introduction

Lung cancer is the most commonly diagnosed cancer and is the leading cause of cancer-related deaths (1). The World Health Organization (WHO) classifies lung cancer into two broad histological subtypes: non-small-cell lung cancer (NSCLC), which underscores 85% of cases, and small-cell lung cancer (SCLC), which accounts for the remaining 15%. NSCLC is further subdivided into adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma (2). Individualized treatment of lung cancer is crucial, and the therapeutic regimens for different subtypes and stages are distinct. The optimal strategy of treatment for stage I and II NSCLC is radical resection, and patients with high recurrence risk may receive combined postoperative radiotherapy (3). For unresectable locally advanced NSCLC, the standard treatment is immunotherapy and concurrent chemoradiation (4). In patients with SCLC, systemic treatment is required as the main or auxiliary treatment, even in the era of limited imaging. For patients with limited-stage SCLC, the goal of treatment is to be cured by chemotherapy and chest radiotherapy. Patients who are fit to undergo radical surgery should after evaluation be administered systemic treatment after surgery and selective mediastinal radiotherapy. Chemotherapy combined with immunotherapy is preferred in patients with extensive-stage SCLC. In addition, systemic therapy alone can alleviate symptoms and appropriately prolong survival in most patients, but long-term survival is generally rare (5). Epidermal growth factor receptor (EGFR) is one of the most common driving genes in NSCLC. Progress in molecular biology research has resulted in EGFR-tyrosine kinase inhibitors (EGFR-TKIs) emerging as the first-line treatment for patients with EGFR-mutant cancer. However, the majority of patients inevitably develop cross-acquired resistance after 9–13 months of treatment with first- and second-generation EGFR-TKIs through various mechanisms (6). The several mechanisms are associated with the development of acquired resistance to EGFR-TKIs, include T790M mutation, c-MET amplification, KRAS mutation, BIM polymorphism deletion, and PIK3CA gene mutations (7). The mechanism of EGFR-TKI resistance and treatment strategies after resistance have become the focus of basic and clinical research. Recently, a growing number of drugs targeting tumor drug resistance mechanisms and related signaling pathways have entered clinical trials. This has resulted in development of immunotherapy and widespread use of immune checkpoint inhibitors (ICI) for the treatment of patients with lung cancer. The 2020 update of the NCCN Oncology Clinical Practice Guidelines (NCCN Guidelines) recommends new first-line immunotherapy regimens for NSCLC, including pembrolizumab monotherapy, pembrolizumab in combination with chemotherapy, and atezolizumab or bevacizumab in combination with chemotherapy (8). For example, the representative drug, pembrolizumab, is a highly selective humanized anti-PD-1 IgG4κ monoclonal antibody. Disrupting the binding of programmed death-1 (PD-1) and its ligand, the key immunomodulatory factor programmed cell death ligand 1 (PD-L1), blocks inhibitory signals in T cells and inhibits the CD8 cytotoxic immune response and resulting anti-tumor immune response (9, 10). Of note, a subset of patients treated with ICIs, such as PD-L1 inhibitors/PD-1 inhibitors, also exhibits transformation to SCLC. In this regard, the transformation of NSCLC to SCLC may constitute a mechanism of action of anti-PD-1/PD-L1 inhibitors.

A minority of patients present with small cell histomorphological transformation of NSCLC, including adenocarcinoma or squamous cell carcinoma, after targeted therapy or immunotherapy. However, transformation to SCLC is considered drug resistance, and the underlying mechanisms remain unclear (11, 12). The transformation of NSCLC to SCLC after targeted therapy or treatment with ICIs alone or in combination with other drugs as anti-tumor therapy has been reported (13–15). Here, we report a case of TKI resistance due to SCLC transformation and another case of tumor transformation from squamous cell carcinoma to SCLC during treatment with pembrolizumab. Our cases emphasize the importance of repeated biopsy in the treatment process and propose a possible source of transformed cells. In addition, we provide a review of the literature and summarize the clinical characteristics of rare SCLC transformation cases with PD-1 inhibitors (12, 15–23).
Case description

Case 1

A 63-year-old woman with no smoking history was admitted for cough and expectoration in June 2020. A computed tomography (CT) scan revealed a 3.3×2.5 cm mass in the lower left lung and multiple mediastinal lymph nodes (Figures 1A, B). After percutaneous puncture lung biopsy, the removed tissues were diagnosed pathologically by immunohistochemistry (IHC) and hematoxylin-eosin (H&E) staining (Figure 1C). IHC staining results indicated that both CK7 and napsin A were expressed in the cytoplasm and were strongly positive, while thyroid transcription factor 1 (TTF-1) was expressed in the nucleus and was positive (Figure 1D). The positive index of Ki-67 was 5%. The diagnosis of left lung invasive adenocarcinoma was considered based on the combined imaging and pathological biopsy results. The genetic testing results revealed EGFR mutation, and targeted therapy with EGFR-TKIs was recommended. The patient was commenced on gefitinib. At 5 months after chemotherapy, the patient presented with dry cough and chest tightness 1 week prior in November 2020. After admission, CT revealed malignant pleural effusion. Routine pleural effusion estimation results of carcinoembryonic antigen (CEA) level showed that they were abnormal and increased. By careful consultation, the patient had discontinued gefitinib for 5 months and switched to traditional Chinese medicine. By dialogue, resumption of targeted therapy usage with gefitinib was suggested. In August 2021, the patient presented with chest tightness and shortness of breath. CT scan results that were compared with previous 9-month images revealed partial enlargement of the left lung lesion and a large plural effusion on the left side (Figure 1E). After symptom relief by pleural effusion drainage, the patient underwent thoracic perfusion. The patient’s symptoms and examination results indicated progressive adenocarcinoma of the left lung that was resistant to gefitinib. The use of third-generation targeted drugs or combined chemotherapy for follow-up treatment after completion of genetic detection of drug resistance in lung cancer was suggested, but this was rejected by the patient. In February 2022, the patient again presented with chest tightness, shortness of breath, and aggravation after activity. Enlarged lymph nodes with hard texture were palpable in the anterior left neck and outer quadrant of the left breast, with poor activity. Review of the chest CT compared to those obtained in August 2021 revealed progression of the lesion in the left lung, with multiple lymph node and organ metastases (Figure 1F). Biopsy was performed after the resection of a 2.0×1.5 cm tumor section on the left chest wall (Figure 1G). IHC staining revealed strong diffuse synaptophysin (Syn) immunopositivity in the cytoplasm, focal weak CD56 immunopositivity in the cell membrane (Figure 1H), and TTF-1 immunopositivity in the nucleus. The positive index of Ki-67 was 90%, and the patient was diagnosed with SCLC.
Tumor markers, tested severally during the patient’s multiple hospitalizations revealed abnormally high CEA levels. Other indicators (CA199, human epithelial protein 4 (HE4), and ferritin) levels were also abnormal, and the last reexamination of serum tumor markers revealed significantly elevated neuron-specific enolase (NSE) levels to 159.00 ng/mL (normal range, 5-15 ng/mL). Suggested continuation of subsequent SCLC chemotherapy was rejected by the patient and her family. Unfortunately, due to progressive disease (PD), the patient eventually died in March 2022 due to respiratory failure caused by acute respiratory distress syndrome (ARDS) combined with acute right pulmonary edema.

Case 2

A 75-year-old Chinese man with a smoking history of 40 pack-years presented with cough. A CT chest scan confirmed a space-occupying lesion on the left hilar and mediastinal lymph node enlargement in March 2020 (Figures 2A, B). Fiberoptic bronchoscopy revealed complete blockage of the upper lobe opening of the left lung. The specimens were biopsied under bronchoscopic guidance with strong positive IHC staining for P40 (Figure 2C) and P63 in the nucleus, and positive expression of CK5/6 and CK7 in the cytoplasm. The Ki-67 positive index was 60%. Specimens were negative for TTF-1 in the nucleus and for napsin-A and Syn (Figure 2D) in the cytoplasm. Even cornified pearls were observed in H&E sections (Figure 2E). The patient was diagnosed with left central squamous cell carcinoma with multiple metastases to both lungs. An adjuvant chemotherapy regimen of carboplatin-paclitaxel was administered and the first cycle of a PD-1 inhibitor, pembrolizumab, was commenced at a dose of 200 mg every 3 weeks from April 2020. The patient was treated for NSCLC with ICIs combined with chemotherapy and exhibited a partial response (Figures 2F, G). The patient completed 15 cycles of immunotherapy by September 2021. Compared to the CT findings in May 2021, a follow-up CT scan revealed tumor progression, metastases, and new lesions in the left lower lung (Figures 2H, I). Serum CEA levels were slightly high (9.27 ng/mL). Referring to the patient’s imaging data, clinicians considered the new lesions to be oligoprogression within an oligometastatic clinical situation. Surgical indications were evident, and the patient underwent neoplasm excision by thoracoscopy, with a 3.0 x 2.5 cm mass in the left lower lobe. Pathological biopsy by surgical excision of the specimen and IHC staining revealed weak focal immunopositivity for CD56, diffuse TTF-1 immunopositivity in the nucleus, and strong...
immunopositivity for Syn (Figure 2J) and CK7 in the cytoplasm. The Ki-67 positive index was 40%. Staining for P40 (Figure 2K), P63, napsin-A, and CK5/6 was negative. Biopsy revealed consistent characteristics with SCLC (Figure 2L). Gene sequencing results indicated the absence of EGFR mutation and ALK translocation. The patient was advised to continue follow-up treatment with ICIs. Immunotherapy with pembrolizumab was commenced in October 2021. As of September 2022, 20 cycles of treatment had been completed, with good clinical outcomes and no significant discomfort.

**Discussion**

In this report, we describe small cell histomorphological transformation of NSCLC after immunotherapy (Case 1) and EGFR-TKI targeted (Case 2) therapy. The common features of both cases were as follows: (1) before the transformation to SCLC, the lesions in both cases were multicentric and imaging results revealed enlarged lymph nodes; and (2) transformation to neuroendocrine SCLC occurred in both cases. Moreover, differences between the two cases were as follows: (1) the patients were of different gender and the male patient had a long history of smoking; (2) the histological types prior to transformation were distinct, whereby Case 1 was lung adenocarcinoma and Case 2 was squamous cell lung carcinoma; (3) different driving genes and molecular changes led to the use of different therapeutic drugs, whereby EGFR-TKI was used for Case 1 and a PD-1 inhibitor was used for Case 2; (4) the patients exhibited distinct therapeutic effects. Case 1 was not sensitive to targeted therapy and showed PD, while Case 2 was sensitive to immunotherapy and stable disease (SD).

Targeted therapy with EGFR-TKIs is often the first-line treatment for lung cancers with EGFR-activating mutations. The most common resistance mechanism is a Thr790Met mutation in EGFR, which has been reported in 50-60% of resistant tumor samples (24). MET and HER2 amplify at low frequencies, accounting for another 15-20% of cases. Histological transformation of EGFR-mutated adenocarcinoma to SCLC was first reported in 2006 as a relatively rare mechanism of resistance (2). Among patients treated with EGFR-TKIs as targeted therapy, this mechanism accounts for 3-15% of transformation to SCLC, particularly transformation from adenocarcinoma to SCLC (25), which may constitute a potential mechanism of acquired drug resistance to EGFR-TKIs (26). Small cell transformation as a resistance mechanism for immunotherapy was first reported in 2017 by Imakita et al. (23). Since then, several similar cases have been reported, and the concept of small cell transformation is well known.

Epithelial-mesenchymal transformation (EMT) has been proposed as a mechanism of acquired resistance to EGFR-TKIs in several preclinical models. Deficiency in apoptosis leads to resistance of EGFR-TKIs in NSCLC with EGFR-mutation, and a reduction in apoptosis is often caused by the lack of expression of the pro-apoptotic gene, the Bcl-2 interacting mediator of cell death (BIM). EMT can antagonize the response to targeted therapy in lung cancer by inhibiting BIM (27). Furthermore, several studies have demonstrated that alveolar type II cells may be common precursors of both lung adenocarcinoma and SCLC. In this regard, SCLC and adenocarcinoma cells may originate from the same cancer stem cells or progenitor cells (28). In addition, amplification of MYC has been observed in the SCLC genome sequencing project. MYCL1 affects the proliferation of SCLC cells, and MYCL1 knockdown weakens the proliferation of SCLC cells, indicating that MYC plays a driving role in the occurrence of SCLC (29, 30). Transformation to SCLC occurs much less frequently in patients with non-EGFR mutations than in patients with EGFR-driven NSCLC (31). Genetic testing before treatment confirmed an EGFR mutation in Case 1, highlighting the risk of transformation. Patients with EGFR exon 19 deletion are also more likely to undergo transformation (26). Another study confirmed that the risk of SCLC transformation is six times higher in patients with concurrent EGFR, TP53, and RB1 mutations than in patients without mutations (25). Moreover, Achaete-scute homolog 1 (ASCL1) can interact with the Rb-p53 (by RB1, TP53 code, respectively) axis to promote the growth of adenocarcinoma with a higher degree of invasion (32).

SCLC transformation occurs predominantly in non-smoking Asian female patients with adenocarcinoma with EGFR-sensitive mutations (33). In this report, Case 1 was an elderly female with no history of smoking and a primary tumor with histological type of lung adenocarcinoma. The patient was treated with gefitinib, a representative drug of first-generation EGFR-TKIs, and exhibited self-discontinuation behavior during treatment. Ofin et al. reported that overall survival (OS) was reduced after discontinuation of EGFR-TKIs compared to that in the normal treatment group (34). Our patient exhibited disease progression after 14 months on gefitinib and was considered resistant to gefitinib. The patient was advised to continue treatment with third-generation EGFR-TKIs. A representative drug, such as ositinib, was recommended for first-line treatment of advanced EGFR-mutated NSCLC based on mutations in Thr790Met (35), but the patient refused this recommendation. Transformation to SCLC was confirmed by biopsy after 6 months of continued disease progression. Due to the limited tissue samples available for this biopsy method, the histological type of the entire tumor could not be determined, the possibility that the primary tumor included an SCLC component could not be excluded (19).

In addition, TP53 and RB1 mutations may be used as predictors of phenotypic transformation in NSCLC with EGFR mutations. TP53 and RB1 double mutations are the most common gene mutations in SCLC. In particular, the incidence
of RB gene inactivation in NSCLC-transformed SCLC is almost 100%. P53 and RB play key roles in cell cycle regulation (36, 37). However, genetic testing was not performed after transformation in Case 1. Hence, there was no evidence for the occurrence of TP53 and RB1 mutations in this patient. In addition, the rapid increase in NSE levels and rapid resistance to EGFR-TKIs were suggestive of the transformation of EGFR-positive lung adenocarcinoma to SCLC (38, 39). Indeed, the transformation of lung adenocarcinoma to SCLC is a risk factor when NSE levels are five-fold higher than normal (40). In our case, the patient also experienced a rapid increase in serum NSE levels prior to transformation, and transformation to SCLC was confirmed after secondary biopsy. Any additional treatment for NSCLC should consider the possibility of transformation to SCLC. In this regard, dynamic monitoring of serum NSE levels and genetic detection of TP53 and RB gene mutations can be used to predict disease progression and SCLC transformation during treatment of patients with EGFR-TKIs. These non-invasive techniques allow monitoring of a patient’s response to treatment. Notably, there is evidence supporting repeated biopsies and timely adjustment of treatment strategies after transformation. Several studies have confirmed that pro-gastrin releasing peptide (pro-GRP) can be used as a marker to predict the transformation from lung adenocarcinoma to SCLC (41). Indeed, this marker has higher diagnostic sensitivity and specificity for SCLC compared to NSE (42). For the clinicians, phenotypic transformation of SCLC poses a great challenge, because effective treatment regimens are lacking, and the precise mechanisms underlying transformation remain unclear. With the emergence of acquired resistance to EGFR-TKIs in patients in recent years, immunotherapy is being increasingly promoted as a treatment option for SCLC.

Compared with the phenomenon of small cell transformation after EGFR-TKI resistance, the use of PD-1 inhibitors for transformation is rare and retrospective studies are lacking. We systematically evaluated the literature and reviewed previous case reports of histological transformation in ICI resistance. We identified 15 cases of small cell transformation through immunotherapy from 10 articles. Relevant case information is presented in Table 1, which summarizes the clinical and genetic features of these cases. Among cases, 11 were men and 4 were women, with an average age of 69 years. Almost all patients had a history of smoking. The primary tumor types included squamous cell carcinoma, adenocarcinoma, and squamous cell carcinoma with neuroendocrine features. The patients were treated with immunosuppressants at the immune checkpoint, and the PD-1 inhibitors used included nivolumab, pembrolizumab, and sintilimab. The best responses to treatment were partial response, progression of disease, and stable disease. The period from the beginning of immunotherapy to the diagnosis of small cell carcinoma transformation ranged from 4 weeks to approximately 3 years. After detection of small cell transformation, regimens for treating SCLC were selected for follow-up treatment. Based on the available survival data of 11 cases, 9 cases died. The average survival time after small cell transformation was 9 months, and two cases exhibited good clinical therapeutic effects. The specific genomic information of these cases is presented in Table 1.

Case 2 was a 73-year-old male patient with an initial diagnosis of squamous cell carcinoma of the lung. A review of the literature revealed that the primary tumor was also predominantly squamous lung carcinoma. The mechanism of histological transformation after treatment with PD-1 inhibitors is thought to be similar to that with the use of EGFR-TKIs. In addition to the aforementioned potential mechanisms of transformation including EMT, RB1, and TP53 inactivation; MYC amplification; and co-origin cells; another possibility is that the original tumor comprised two histological components (43). However, SCLC with neuroendocrine characteristics may have been missed due to insufficient pathological materials for mixed histological diagnosis. In the process of PD, the SCLC component dominates. With a decrease in the number of treatment-sensitive NSCLC cells, the SCLC components that initially existed in tumors with higher malignancy gradually dominate. Our patient received a carboplatin-paclitaxel combined chemotherapy regimen in addition to ICIs before the occurrence of drug resistance. As such, the influence of other drugs in the combined treatment regimen on histological transformation of the tumor should be considered. In addition, molecular genetic changes in patients during treatment were inadequately monitored.

Based on imaging results, our patient exhibited tumor progression after 15 cycles from the start of immunotherapy. Transformation was confirmed after surgical resection for biopsy, with no EGFR mutation or ALK translocation after transformation. The antitumor activity of pembrolizumab in patients with PD-L1-positive tumors has been demonstrated in a KEYNOTE-028 multi-cohort study (44). The patient is currently continuing treatment with pembrolizumab. After a thorough evaluation of the lesion, the metastases in the left lower lung that developed in this patient after immunotherapy was considered as oligometastatic. Oligometastasis is a transitional stage between a localized primary tumor and widespread metastases, defined as the presence of one to five metastases from a malignant tumor in a distant organ (45). The oligometastatic phase can occur in a variety of clinical situations: patients with a clear and limited number of metastases at diagnosis; patients with multiple metastases with limited residual disease after systemic therapy, or progression of only one lesion after conventional therapy (oligoprogression), or recurrence of localized lesions after treatment (oligorecurrence) (46). Regular monitoring of lesion progression or metastasis during targeted therapy or immunotherapy can help to detect the emergence of new clinical conditions such as oligometastasis in time. The adoption of aggressive local therapeutic approaches, for
| Reference | Age/sex at NSCLC dx | Smoking history | Histology and clinical staging | Genomic profile | Treatment of ICIs | Best response to ICIs | Histologic Transformation | Treatment for transformation | Life cycles after SCLC dx | Time from ICI start to SCLC dx | Patients outcome |
|-----------|---------------------|-----------------|--------------------------------|-----------------|------------------|---------------------|------------------------|---------------------------|---------------------------|-----------------------------|-------------------------|
| 1 Case 2  | 75 M 40 pack-years  | Sq              | P40, P63(+), CKS3(6+), TTF-1(-) | Pembrolizumab/15 cycles | PR               | SCCL                | Pembrolizumab           | –                         | 18 months               | Clinically well            |
| 2 Takuma Imakita (12)  | 64 M 84 pack-years  | Sq, stage IIIa  | –                              | Nivolumab/23 cycles | PR               | LCNEC/SCCL          | CBDCA/CPT, AMR          | –                         | 29 months/33 months         | –                        |
| 3 Qian Shen (15)  | 69 M 30 pack-years  | Sq, stage IVa   | PD-L1<50%                      | Sintilimab/4 cycles | SD               | SCCL                | ETP                    | <1 month                 | 2 months                  | Died                     |
| 4 Kartik Sehgal (16)  | Mid-60s F 35 pack-years | Sq, stage IV    | TP53 mut, CDKN2A R58 mut       | Pembrolizumab/6 cycles | PR               | SCCL                | CBDCA/ETP/Nivolumab/XRT | 14 months                | 21 months                  | Died                     |
| 5 Naoko Miura (17)  | 65 M 34 pack-years  | Ad, stage IVb   | EML4-ALK(-), PD-L1(++)         | Pembrolizumab/22 cycles | PR               | SCCL                | CBDCA/ETP              | –                         | 14 months                  | Lesions decreased         |
| 6 Xiaoyan Si (16)  | 69 M 48 pack-years  | Sq, stage IV    | PD-L1<1%                       | Pembrolizumab/22 cycles | PR               | SCCL                | CBDCA/ETP              | –                         | 14 months                  | Lesions decreased         |
| 7 Jair Bar (19)  | 70 F current 10 pack-years | Sq with neuroendocrinefeatures | P40, CKs6 (+), CK56 (+), TTF-1(-) | Nivolumab/3 cycles Nivolumab/10 months | PD/SD         | SCCL/Mixed neuroendocrine and Sq | Nivolumab | Alive 9 months post SCLC dx; then lost to follow-up | 16 months | –                        |
| 8 Komugi Okeya (20)  | 66 M 45 pack-years  | Ad, stage IVb   | EGFR(+), ALK(-), PD-L1 90-100% | Pembrolizumab/2 cycles | Hyper PD       | SCCL                | CBDCA/ETP/AMR           | 4 months                  | 5 weeks                    | Died                     |
| 9 Wade T. Iams (21)  | 67 F 50 pack-years  | Ad               | –                              | Nivolumab/36 cycles | PR               | SCCL                | CBDCA/EPT/TAX           | 11 months                 | 19 months                  | Died                     |
| 10 Nadine Abdullah (22)  | 65 M 35 pack-years  | Ad, stage IVa   | EGFR mut, ALK(+)              | Nivolumab/5 cycles | PD               | SCCL                | CBDCA/EPT              | –                         | after 5 cycles of ICI     | –                        |

(Continued)
example, surgical resection, can then provide opportunities for disease control and good prognosis for patients (47). Researchers noted that surgery provided a better prognostic effect for the oligometastatic stage IV NSCLC. For example, when patients with NSCLC develop extrathoracic distant metastasis, the most common site is the brain, and the mean survival time in the group with and without complete surgical resection of brain metastases was 15.4 and 11.5 months, respectively (P=0.002). With adrenal metastases, the mean survival time was 31.1 and 11.3 months in the surgical and non-surgical resection groups, respectively (P=0.001) (48). These data indicate that surgery appears to provide survival benefit when patients develop oligometastasis during treatment.

Survival prognosis after the occurrence of SCLC transformation is poor due to the rapid progression of SCLC and limited surgical treatment. In patients with progressive disease, the average survival time is 6 months, and survival is correlated with smoking status (49). In our patients, after SCLC transformation, the elderly female patient (Case 1) developed a series of complications leading to rapid deterioration and death due to refusal to continue treatment, while the male patient (Case 2) is currently continuing immunotherapy and is in a good general condition.

Conclusion

In conclusion, we report two cases exhibiting transformation from NSCLC to SCLC after different treatment regimens. Our findings suggest that tumor cells may transform to a more aggressive histological type once resistance occurs, regardless of treatment with ICIs or EGFR-TKIs. The occurrence of histological transformation may be underscored by genomic mutations. This highlights the importance of monitoring serum tumor markers or repeated biopsy using genome sequence. Furthermore, multi-point sampling detection can conduct at the initial diagnosis to reduce the possibility of missed diagnosis of SCLC and facilitate the discovery of drug resistance mechanisms.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

Author contributions

YQ, LC, and LP contributed to conception and design of the study. JD and SZ collected information of case. HL wrote the first
draft of the manuscript and organized the data. YQ and NW wrote sections of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by grants from the National Natural Science Foundation of China (grant no. 81860471); Zhanjiang science and technology development special fund Competitive Allocation Project - key projects of disease prevention and control (2021A05145); Provincial Science and technology special fund (“College items+ task list”) project - special topic of basic and applied research (2021A05236).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
26. Yang H, Liu L, Zhou C, Xiong Y, Hu Y, Yang N, et al. The clinicopathologic characteristics of pulmonary adenocarcinoma transformation to small cell lung cancer. *Med (Baltimore).* (2019) 98(12):e14893. doi: 10.1097/md.00000000000014893

27. Song KA, Niederst MJ, Loochmann TL, Hata AN, Kitai H, Ham J, et al. Epithelial-to-Mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing HM. *Clin Cancer Res* (2018) 24(1):197–208. doi: 10.1158/1078-0432.Ccr-17-1577

28. Jiang Y, Shou L, Guo Q, Bao Y, Xu X, An S, et al. Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report. *Med (Baltimore).* (2021) 100(32):e26911. doi: 10.1097/md.0000000000026911

29. Peters M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify somatic driver mutations of small-cell lung cancer. *Nat Genet* (2012) 44(10):1104–10. doi: 10.1038/ng.2396

30. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. *Nat Genet* (2012) 44(10):1111–6. doi: 10.1038/ng.2405

31. Ferrer L, Giaj Levra M, Brevet M, Antoine M, Mazieres J, Rossi G, et al. A brief report of transformation from NSCLC to SCLC: Molecular and therapeutic characteristics. *J Thorac Oncol* (2019) 14(1):130–4. doi: 10.1016/j.jtho.2018.08.2028

32. Meder L, König K, Oezretic L, Schultheis AM, Ueckeroth F, Ade CP, et al. NOTCH, ASCL1, p53 and RB alterations de ne an alternative pathway driving neuroendocrine and small cell lung carcinomas. *Int J Cancer.* (2016) 138(4):927–38. doi: 10.1002/ijc.29835

33. Shimatusu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst* (2005) 97(5):339–46. doi: 10.1093/jnci/dji055

34. Oliff M, Chan JM, Tenet M, Rzvi HA, Shen R, Rilley GJ, et al. Concurrent RB1 and TP53 alterations de ne a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. *J Thorac Oncol* (2019) 14(10):1784–93. doi: 10.1016/j.jto.2019.06.002

35. Soria JC, Obi Y, Vansteenkiste J, Reungsupawatana T, Chawaskulyong R, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced Non-Small-Cell lung cancer. *N Engl J Med* (2018) 378(2):113–25. doi: 10.1056/NEJMoa1713137

36. Rudin CM, Brambilla E, Faire-Finn C, Sage J. Small-cell lung cancer. *Nat Rev Dis Primers.* (2021) 7(1):3. doi: 10.1038/s41572-020-00235-0

37. Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, et al. Cells lacking the RB1 tumor suppressor gene are hyperdependent on aurora b kinase for survival. *Cancer Discovery* (2019) 9(2):230–47. doi: 10.1158/2159-8290.Cd-18-0389

38. Meder L, König K, Fassunke J, Ozretic L, Wolf J, Merkelbach-Bruse S, et al. Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases. *Exp Mol Pathol* (2015) 99(3):682–6. doi: 10.1006/jexpmp.2015.11.002

39. Niederst MJ, Sequist LV, Poirier JT, Merdel CH, Lockerman EL, Garcia AR, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. *Nat Commun* (2015) 6:6377. doi: 10.1038/ncomms7377

40. Zhang Y, Li XY, Tang Y, Xu Y, Guo WH, Li YC, et al. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma? *Lung Cancer* (2013) 81(2):302–5. doi: 10.1016/j.lungcan.2013.04.005

41. Liu Y. Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review. *Cancer Biol Ther* (2018) 19(6):445–9. doi: 10.1080/15384047.2018.1435222

42. Oya Y, Yoshida T, Uemura T, Murakami Y, Inaba Y, Hida T. Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: A case report. *Oncol Lett* (2018) 16(4):4219–22. doi: 10.3892/ol.2018.9158

43. Ahn S, Hwang SH, Han J, Choi YL, Lee SH, Ahn JS, et al. Transformation to small cell lung cancer of pulmonary adenocarcinoma: Clinicopathologic analysis of six cases. *J Pathol Transl Med* (2016) 50(4):258–63. doi: 10.4132/jptm.2016.04.19

44. Olt PA, Elez E, Hirtel S, Kim DW, Morosky A, Saraf S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: Results from the phase ii KEYNOTE-028 study. *J Clin Oncol* (2017) 35(34):3823–9. doi: 10.1200/jco.2017.72.5069

45. Berzenji L, Debeanst S, Hendriks JMH, Yogeswaran SK, Lauwers P, Van Schil PE. The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review. *Transl Lung Cancer Res* (2021) 10(7):3409–19. doi: 10.21037/tlcr-21-58

46. Hellman S, Weichselbaum RR. Oligometastases. *J Clin Oncol* (1995) 13(1):8–10. doi: 10.1200/jco.1995.13.1.8

47. Novoa NM, Varela G, Jimenez MF. Surgical management of oligometastatic non-small cell lung cancer: a literature review. *Transl Lung Cancer Res* (2021) 10(Suppl 11):S895–900. doi: 10.21037/tlcr.2021.08.13

48. Xu Q, Wang Y, Liu H, Meng S, Zhou S, Xu J, et al. Treatment outcome for patients with primary NSCLC and synchronous solitary metastasis. *Clin Transl Oncol* (2013) 15(10):802–19. doi: 10.1007/j10195-013-1008-2

49. Roca E, Gurizzan C, Amoroso V, Vermi W, Ferrari V, Berruti A. Outcome of patients with lung adenocarcinoma who develop small cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis. *Cancer Trust Rev* (2017) 59:117–22. doi: 10.1016/j.ctrv.2017.07.007